Form 4: NextCure Executive Acquires Stock Options

NextCure's Chief Operating Officer, Timothy Mayer, was granted stock options for 117,375 shares of common stock.

Summary

• Timothy Mayer, the Chief Operating Officer of NextCure, Inc., was granted employee stock options on January 31, 2025.
• The options are for 117,375 shares of NextCure common stock.
• The exercise price of the options is $0.8048 per share.
• One fourth of the options will vest on January 31, 2026, with the remainder vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative or unexpected events.

Positives

• The granting of stock options to the COO aligns his interests with the company's long-term performance.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector where long-term growth is a key focus.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options to align executive interests with shareholder value.
• The vesting schedule of these options is typical, with a portion vesting after one year and the remainder over the following years.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the COO to work towards long-term company success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, NextCure, NXTC, equity, vesting